Armistice Capital’s bioAffinity Technologies BIAFW Stock Holding History

Armistice Capital’s Portfolio BIAFW Stock Details BIAFW Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q3	–	Sell	-204,082	Closed	-$26.5K	–	342
2025 Q2	$26.5K	Hold	204,082	–	–	﹤0.01%	194
2025 Q1	$38.8K	Hold	204,082	–	–	﹤0.01%	214
2024 Q4	$68.7K	Hold	204,082	–	–	﹤0.01%	208
2024 Q3	$235K	Hold	204,082	–	–	﹤0.01%	213
2024 Q2	$61.3K	Hold	204,082	–	–	﹤0.01%	235
2024 Q1	$156K	Hold	204,082	–	–	﹤0.01%	298
2023 Q4	$17.6K	Hold	204,082	–	–	﹤0.01%	276
2023 Q3	$18.6K	Hold	204,082	–	–	﹤0.01%	240
2023 Q2	$105K	Sell	204,082 -1	-0%	–	﹤0.01%	188
2023 Q1	$61.2K	Buy	204,083 +1	+0%	–	﹤0.01%	204
2022 Q4	$85.7K	Hold	204,082	–	–	﹤0.01%	166
2022 Q3	$72K	Buy	+204,082	New	+$212K	﹤0.01%	187

Other funds holding BIAFW

Clear Street New York $24.6B AUM 56.26% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Armistice Capital's BIAFW Position: Q3 2025 in Review

Armistice Capital sold out of bioAffinity Technologies (BIAFW) in Q3 2025, closing a stake of 204,082 shares — an estimated $26.5K sold.

Armistice Capital first reported a position in BIAFW in Q3 2022 and held it in 12 quarters. The position peaked at $235K in Q3 2024. 3 funds tracked by Wall St. Rank hold BIAFW as of Q3 2025.

Armistice Capital reported no remaining bioAffinity Technologies position as of Q3 2025 after selling out during the quarter.
Armistice Capital sold 204,082 bioAffinity Technologies shares in Q3 2025, an estimated $26.5K.
Armistice Capital first reported a position in bioAffinity Technologies in Q3 2022 and held it in 12 quarters.
Armistice Capital's bioAffinity Technologies position peaked at $235K in Q3 2024.
3 funds tracked by Wall St. Rank held bioAffinity Technologies as of Q3 2025.

Based on Armistice Capital's 13F filing for Q3 2025, filed 17 Nov 2025.